| AGM Date |
Company |
Market |
Annual Report |
SIAS Questions |
Company Response |
Array
(
[0] => WP_Post Object
(
[ID] => 4361
[post_author] => 1
[post_date] => 2018-07-26 19:42:19
[post_date_gmt] => 2018-07-26 11:42:19
[post_content] =>
[post_title] => iX Biopharma Ltd
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => ix-biopharma-ltd-2
[to_ping] =>
[pinged] =>
[post_modified] => 2018-07-26 19:42:19
[post_modified_gmt] => 2018-07-26 11:42:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd-2/
[menu_order] => 0
[post_type] => annual_reports
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4129
[post_author] => 1
[post_date] => 2018-07-26 19:40:39
[post_date_gmt] => 2018-07-26 11:40:39
[post_content] =>
[post_title] => iX Biopharma Ltd
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => ix-biopharma-ltd
[to_ping] =>
[pinged] =>
[post_modified] => 2018-07-26 19:40:39
[post_modified_gmt] => 2018-07-26 11:40:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd/
[menu_order] => 0
[post_type] => annual_reports
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
Array
(
[cid] => 4361,4129
[company] => iX Biopharma Ltd
)
Array
(
[post_type] => annual_reports
[showposts] => 12
[meta_key] => agm_date
[orderby] => Array
(
[meta_value] => DESC
[title] => ASC
)
[order] => DESC
[paged] => 1
[post_title_like] => iX Biopharma Ltd
[meta_query] => Array
(
[key] => mark_as_upcoming_qa
[value] =>
[compare] => =
)
)
| AGM Date: 24/10/2017 |
24/10/2017 |
Company: iX Biopharma Ltd |
iX Biopharma Ltd |
Market: Catalist |
Catalist |
Annual Report: Download |
Download |
SIAS Questions | 1. The group report a revenue increase of 10% to $6.4 million in 2017...
2. The group has developed a new pipeline of nutraceutical products and...
3. As disclosed in the Corporate Governance Report (page 29), a sum of $130,000... Read More | Company Response | 1. Revenue of Chemical Analysis increased 7% in FY2017 over FY2016. There...
2. We have identified 5 major regions in which we are exploring launching...
3. During FY2017, Centrum Capital had been engaged to provide... Read More |
| AGM Date: 25/10/2016 |
25/10/2016 |
Company: iX Biopharma Ltd |
iX Biopharma Ltd |
Market: Catalist |
Catalist |
Annual Report: Download |
Download |
SIAS Questions | 1. New drug application is extremely costly and time consuming and shareholders may not be...
2. For the benefit of the current shareholders, the group must manage its expenses and cash...
3. In the Remuneration section in the Corporate Governance report (page 19), the... Read More | Company Response | 1. Product: Wafermine™ Sublingual ketamine; PheoniX™ Sublingual...
2. Excluding share - based compensation, clinical t rials and...
3. RC commissioned Carrots Consulting to review the... Read More |
